After $356M in Federal Funds in Dec, Merck Secures $1.2B Federal Commitment to Buy its Experimental Drug Upon Key Milestones

After $356M in Federal Funds in Dec, Merck Secures $1.2B Federal Commitment to Buy its Experimental Drug Upon Key Milestones

Another brilliant corporate showcasing enterprising business prowess or yet another example of crony capitalism on display for the world to see? That’s the question many are asking as Merck continues to progress its agenda to finally monetize the pandemic with an experimental drug that’s been around for many years. The company just announced it secured a $1.2 billion public commitment for up to $1.7 million courses of its still experimental antiviral drug Molnupiravir to the United States government. Merck already secured $356 million of taxpayer money for another COVID-19 drug that they subsequently shelved. Perhaps this explains why Merck went on the aggressive against the ivermectin generic alternative currently under investigation by the U.S. government as well in the ACTIV 6 program.  The U.S. government has agreed to pay about $705 per course should Merck successfully progress the drug through Phase 3 and to an emergency use authorization (EUA) or regulatory approval milestone. Merck, along with Roche, Pfizer, and a few others, continue their quest to capture what is a highly lucrative COVID-19 early-onset, mild-to-moderate symptom antiviral treatment mar...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee